Yoshifumi Torii, Ph.D.

Dr. Torii is the Global R&D Head, Executive Officer, and Vice President of Kyowa Kirin Co., Ltd., a Japan-based global specialty pharmaceutical company. In 1994 he started his career as a scientist in hematology in pharmaceutical labs in Kirin Brewery, and has experienced several functions including clinical development, project management, project lead, product strategy planning and so on. He led the development of cinacalcet, an Ca- sensing receptor agonist in collaboration with Amgen, and successfully obtained approval from health authority in Japan. In 2013 he was seconded to Fujifilm Kyowa Kirin Biologics (FKB) and established its European Branch in UK. He led global clinical programs of biosimilars of adalimumab and bevacizumab as General Manager of European Branch. In 2017 he was appointed CEO and President of FKB. In 2000 he returned to Kyowa Kirin and appointed current position.

Dr. Torii received an undergraduate degree from the University of Tokyo with a major in Pharmacology. He received his Ph.D. degree in 1994 from the University of Tokyo, and joined Kirin.